Robyn Moran, DO
Rheumatology · Topeka, KSNPI 1609257476
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 138 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $873 and has fallen 93.3% since, to $58 in 2025.
Across 138 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$528
- Amgen$458
- Pfizer$257
- Johnson & Johnson$221
- AstraZeneca$178
- UCB, Inc.$176
- plus $883 from 14 others
What the payments were for
- Food & beverage$2,701100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $528 |
| Amgen | 19 | $458 |
| Pfizer | 16 | $257 |
| Johnson & Johnson | 11 | $221 |
| AstraZeneca(2 entities) | 9 | $178 |
| UCB, Inc. | 9 | $176 |
| Sobi, Inc | 5 | $140 |
| Novartis | 6 | $124 |
| GSK | 5 | $90 |
| Mallinckrodt Hospital Products Inc. | 4 | $79 |
| Genentech USA, Inc. | 4 | $77 |
| Boehringer Ingelheim | 3 | $76 |
| Organon | 3 | $71 |
| Lilly USA, LLC | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Aurinia Pharma U.S., Inc. | 2 | $33 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Hospira, Inc. | 1 | $15 |
How this compares
$2,701 in reported general payments places this provider in the 60th percentile of 49 rheumatology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 14 | $95,248 |
| Hydroxychloroquine Sulfate | 185 | $8,507 |
| MethotrexateMethotrexate Sodium | 82 | $2,930 |
| Sulfasalazine DrSulfasalazine | 20 | $2,160 |
| Prednisone | 127 | $996 |
| Sulfasalazine | 26 | $970 |
| Methotrexate SodiumMethotrexate Sodium/Pf | 27 | $507 |
| Celecoxib | 29 | $336 |
| Leflunomide | 11 | $275 |
| Omeprazole | 11 | $252 |
| Tramadol Hcl | 17 | $158 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Topeka
- Vijay MhatreTopeka$900
- John GardnerTopeka$222
- Edward LetourneauTopeka$39
- James AndersonOverland Park$75K
- Shashank RadadiyaKansas City$74K
- Timothy ShaverWichita$39K
- Stephen RuhlmanOverland Park$32K
- Shadi ShahouriWichita$31K
- Arnold KatzOverland Park$25K
- Aruna BarathamOverland Park$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.